

PuriCore to Present Clinical Case Findings for Vashe® Wound Therapy at SAWC

Three Conference Posters Plus Lecture Sessions on Hypochlorous Acid Solutions in Wound Management

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 23 April 2008 — PuriCore (LSE: PURI), the life sciences company focused on the control of infectious pathogens with its patented, safe, and natural antimicrobial technology, will feature its latest developments and clinical results for its proprietary Vashe Wound Therapy Solution at the Symposium on Advanced Wound Care this week in San Diego, California. PuriCore's technology mimics the human body's production of the natural antimicrobial hypochlorous acid. Hypochlorous acid is highly effective against a broad range of micro-organisms including MRSA, VRE, and numerous other bacteria, viruses, and fungal spores.

The Vashe Wound Therapy Solution is designed as a safe and effective non-cytotoxic, non-sensitizing, wound treatment specifically aimed at managing the wound environment. To date, it has been used in more than 2,500 clinical cases including chronic and acute wounds. The data reflects the positive impact the Vashe Wound Therapy Solution has on the wound environment and subsequently, the healing process. Michel H.E. Hermans, MD, a worldwide thought leader in wounds and burn care, will present these clinical results at the PuriCore Booth #1103 throughout the conference.

Additionally, Jeffrey Niezgoda, MD, FACHM, FAPWCA, FACEP, a leading wound management physician, will present three poster/abstracts at this conference related to his clinical experience using the Vashe Wound Therapy Solution as part of the plan of care in managing a broad range of acute and chronic wounds:

- "Hypochlorous Acid Solution Improves Wound Healing Trajectories"
- "Hypochlorous Acid Solution is Effective in the Treatment of Chronic Venous Ulcers"
- "Hypochlorous Acid Enhances the Treatment of Necrotizing Soft Tissue Wounds"

"Our research indicates that hypochlorous acid represents a new and effective class of treatment for hard-to-heal wounds," said Greg Bosch, CEO of PuriCore. "We are very pleased with our promising clinical results showing both safety and potential therapeutic value in the management of such a wide variety of chronic and acute wounds, and we look forward to expanding our clinical work in this area."

About the Vashe Wound Therapy System

PuriCore's patented wound therapy technology is being commercialized as the Vashe Wound Therapy System, a novel, noninvasive, easy-to-use wound management process that has been shown to be complementary to existing treatment methods. The Vashe System is an FDA-cleared medical device used for moistening, irrigating, cleaning, and debriding acute and chronic wounds including stage I through IV pressure ulcers, stasis ulcers, diabetic ulcers, post-surgical wounds, first and second degree burns, abrasions, and minor irritations of the skin. The Vashe Solution mimics the human body's own infection fighter, hypochlorous acid. Research to date demonstrates that the Vashe Solution provides a safe and effective alternative to cytotoxic antimicrobial and antiseptic products currently used to treat infected wounds and surgical sites and is an important element in the overall clinical process of effective wound management.

About PuriCore

PuriCore (LSE: PURI) is a life sciences company focused on developing and commercializing proprietary products that safely, effectively, and naturally kill contagious pathogens. PuriCore's technology provides a solution to a broad range of markets that depend upon controlling contamination, including food safety in retail and foodservice, medical device disinfection, wound therapy, and hospitality. The Company's proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, which is highly effective in killing bacteria, viruses, and fungal spores. Deploying hypochlorous acid solutions as soaks, sprays, mists, and in other forms, PuriCore's technology is designed to limit the spread of infectious disease, including major public health threats of *M. tuberculosis*, *MRSA*, *E.coli*, Norovirus, Avian Influenza, HIV, Polio Virus, *Helicobacter pylori*, and *Legionella*. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford, UK.

To receive additional information on PuriCore, please visit PuriCore's website at www.puricore.com, which does not form part of this press release.

Enquiries:

Ben Brewerton	Greg Bosch, CEO
Susan Quigley	Keith A. Goldan, CFO
Financial Dynamics	PuriCore
+44 (0) 20 7831 3113	+1 484 321 2700